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Abstract: This special issue of the Turkish Journal of Medical Sciences is dedicated to providing scientific advances in the process of
better understanding the SARS-CoV-2 virus that causes the COVID-19 infection. The special issue is published in a special time in
which science-based approaches, cocreation-based collaboration, and the effective utilization and integration of competences have a
crucial role during the race against time while combating the COVID-19 pandemic. In this process, the Scientific and Technological
Research Council of Turkey (TÜBİTAK), which publishes academic journals including the Turkish Journal of Medical Sciences, has
taken rapid action to mobilize the research community. This includes forming new scientific coalitions in record time, the opening of
new calls across the research ecosystem, the organization of a virtual scientific conference, and the launch of a new portal in support
of cocreation processes and open science. In addition, various teleconferences that bring together various disciplines at the national
and international level have taken place. All of these efforts provide multiple venues to support the common effort of combating the
COVID-19 pandemic with R&D and development as a common objective. The sharing of evidence-based knowledge and scientific
progress is an effective approach towards providing important contributions for combating the COVID-19 pandemic. The research
articles that are contained in this special issue of the Turkish Journal of Medical Sciences involves a special collection dedicated to
COVID-19. This short communication aims to provide an introduction of the major initiatives that have been taken in the scientific
landscape with a focus on Turkey.
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Cocreation in the COVID-19 Turkey Platform for
Vaccine and Drug Development
The importance that TÜBİTAK has given to the
establishment of cocreation models has been represented
in such initiatives as the TÜBITAK 1004 Call for High
Technology Platforms prior to the COVID-19 pandemic.
The first phase of 17 High Technology Platforms that were
already launched in the leadership of research universities
and research centers with competence under Law 6550
on Supporting Research Infrastructure had also included
platforms on drug and vaccine development. In particular,
diagnostic kits, drug and vaccine development including
those for influenza-based infections as well as bioindicator
and high technology drug products and prototype vaccines
had taken place among the focus areas of the research
programs of these platforms.1

As a fast track option with a particular focus on
COVID-19, a subplatform under the coordination of
TÜBİTAK Marmara Research Center (MAM) Genetic
Engineering and Biotechnology Institute has been
established, namely the COVID-19 Turkey Platform. The
subplatform brings together projects and competencies that
can be transformed for an effective response against the
COVID-19 infection with a particular focus on medicine,
vaccines, and innovative treatment approaches. Remarkably,
the orchestration of researchers for the COVID-19 Turkey
Platform and the time for the implementation of the projects
have been completed in a record time of only 10 days.2
Such a scientific coalition brings together researchers
from universities, public R&D units, and the industry
together to work on drug repurposing, drug development,
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innovative treatment approaches, and vaccine development
against COVID-19. The platform currently involves 7
different vaccine and 8 different drug development projects
where both chemical and biotechnological methods
are applied. Multiple methods that have the potential of
enabling an effective response in support of combating
the COVID-19 infection are undertaken. For the grand
goal of supporting an effective, science-based response to
the COVID-19 pandemic, hundreds of researchers from
24 universities, 8 public R&D units, and 8 private sector
firms are working diligently. There are currently 225
researchers with tasks in the platform of which 116 are
from universities, 62 are from public R&D units, and 47
are from the private sector. Overall, the platform involves a
total of 15 projects that are being supported for a duration
of up to 9–12 months.
The Health Institutes of Turkey (TÜSEB) under the
Ministry of Health is collaborating to support the clinical
trials of platform developments. This collaboration
will enable the projects that are supported under the
COVID-19 Turkey Platform to be translated into new
products and treatments.
Recent updates from the COVID-19 Turkey Platform
can be summarized based on the following:
- In silico modeling studies of FDA approved or
Turkey Pharmaceuticals and Medical Devices Agency
(TITCK) licensed drugs are undertaken to determine
drug repurposing candidates that are to be tested for
COVID-19 treatments. These studies are initiated to test
the effectiveness of such drugs and to test their effectiveness
based on in vitro studies.
- Virus isolation for SARS-CoV-2 is accomplished in
Turkey, first by the Head of the Department of Virology
of Ankara University Faculty of Veterinary Medicine
and Director of the Institute of Biotechnology who is
responsible for the project “Development of GriffithinBased Antiviral Approach for the COVID-19 and
Investigation of its Effectiveness” under the COVID-19
Turkey Platform, with additional virus isolation results
taking place.
- Important advances have been made for the
application of convalescent plasma for critically ill
COVID-19 patients. Studies at Acıbadem Labcell and
İstanbul Medeniyet University have reached the final stage.
Detection of donors and appropriate plasma donations
are being checked. Transfusion to the patients will begin
following the arrival of ELISA kits for the determination of
plasma RT-QPCR and COVID-19 IgG/IgM titers.

- Together with İstanbul Medeniyet University, viral
RNA is obtained from samples taken from patients and
sequencing studies are initiated by TÜBİTAK MAM
Genetic Engineering and Biotechnology Institute (GMBE).
In the study, the SARS-CoV-2 virus genome that has been
isolated by Ankara University is in the process of being
sequenced.
- qPCR tests designed by TÜBİTAK MAM GMBE
have been completed and validated by comparison
with commercial kits. The institute is able to perform
COVID-19 qPCR tests or screening when needed and this
capability has been shared with the Ministry of Health.
- Neutralizing antibody library scans were initiated by
obtaining RNA in the biosafety level BSL3 lab from blood
from patients and healthy individuals in the development
project of neutralizing antibodies against COVID-19.
Collection of COVID-19 samples are ongoing.
COVID-19 Turkey Platform Vaccine and Medicine
Development Virtual Meeting
On April 2, 2020, The Ministry of Industry and
Technology of the Republic of Turkey and TÜBİTAK
organized “The COVID-19 Turkey Platform Vaccine and
Medicine Development Virtual Meeting” that focused on
drug repurposing, drug development, innovative treatment
approaches, and vaccine development. In total, 14 speakers
attended the meeting that was arranged in 3 sessions. The
meeting was livestreamed online via YouTube, Twitter, and
Facebook for the access of the public. The livestreaming
received a very high interest with about 130,000 viewers.
The virtual conference included opening statements
from the Minister of Industry and Technology and the
President of TÜBİTAK. The opening remarks underlined
the importance of science-based solutions based on
cocreating together and achieving together within the
research ecosystem. In particular, the first session of
the virtual conference was held with a focus on “DrugRepurposing and Drug Development,” which was followed
by the second session on “Convalescent Plasma and
New Generation Treatment Methods.” The third session
included presentations on “Vaccines ”.3
A New Virtual Portal – The COVID-19 Turkey Web
Portal
TÜBİTAK recognizes the importance of utilizing
virtual environments effectively in the process of
combating COVID-19. For this reason, a first-of-itskind web portal was established that includes scientific
developments regarding COVID-19 as well as a clear
and transparent reporting of daily statistics (Figure). The
virtual scientific portal is established by the Ministry of
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Figure. COVID-19 Turkey Web Portal 4.

Industry and Technology of the Republic of Turkey and
TÜBİTAK, namely the COVID-19 Turkey Web Portal.4
The portal includes recent developments, the competences
of the Turkish ecosystem in related disciplines and
sectors, and a Scientific Sharing Platform for competent
researchers. Open science resources with a particular focus
on COVID-19, including open-access publications, open
access collections, and open data sets, are included from
both national and international databases. Related research
calls of TÜBİTAK, TÜSEB, the European Commission,
and others are also announced. The portal has received
more than 1.6 million visits from 210 thousand visitors
since March 26, 2020.
Intern Researcher Scholarship Program (STAR) for
COVID-19 Research Projects
Another important aspect of mobilizing the research
ecosystem for supporting a science-based combat with
the COVID-19 pandemic is through motivating human
resources. A rapid call is launched with a focus on supporting
the participation of young scholars in COVID-19 related
research topics while reaching important milestones of the
research projects. Undergraduate, graduate, doctorate, and
postdoctoral researchers are provided the opportunity of

being supported with the Intern Researcher Scholarship
Program (STAR) to participate in projects in the fight
against COVID-19. The call aims to contribute to the fight
against COVID-19, to minimize and control the spread of
the epidemic in society, to protect public health, especially
risk groups, and to mitigate the negative socio-economic
effects of the epidemic.5 From the perspective that the
“coronavirus is not stronger than the measures that are
taken,” the call aims to increase the potential of young
researchers to cooperate in the research ecosystem. The
COVID-19 Projects Scholar Demand Interface was also
created on the COVID-19 Turkey Web Portal to provide
an opportunity for candidates who wish to apply under the
call to meet with demands in COVID-19 projects.6
Increased Interaction between Researchers Across
Disciplines and Countries
A teleconference was held between representatives
of the COVID-19 Turkey Platform and members of the
Coronavirus Science Committee of the Ministry of Health of
the Republic of Turkey, including experts in rheumatology
and hematology, with the aim of sharing experiences and
discussing common needs. At the international level, a
teleconference was held with representatives of Academia
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Sinica as the science academy of Taiwan. TÜBİTAK is
dedicated to increasing interactions between researchers
across disciplines and countries during COVID-19.
The Rapid COVID-19 Call under the Support
Program for SMEs
TÜBİTAK established a rapid funding mechanism
for SMEs that have research activities on COVID-19
diagnosis, protective and medical equipment as well as
ICT solutions.7 As another rapid response measure, the
special, fast track call was effective for a duration of 1
week for the project applications while the next 1 week
duration for the project evaluation continues. The entire
process from call launch to the determination of the
supported projects will last 2 weeks. The call focused on
COVID-19 to support projects for the development of
products that can be used in the diagnosis and treatment
of COVID-19 and protective equipment that are effective
in the prevention of the disease. The applications for the
call were much higher than expected. In total, 444 project
applications for the call were received from SMES in the
scope of combating COVID-19.8 Beyond the target of
funding 10 projects, a total of 35 projects received support
decisions after evaluation.
The call covered the following solutions but did not
exclude other COVID-19 related proposals. The funded
projects will receive support lasting up to 9 months,
enabling a fast track to market.
· Disinfectants
· Masks
· Protective clothing
· Diagnostic kits with verification criteria (sensitivity,
specificity, accuracy, precision, linearity) within
internationally accepted limits
· Devices used in intensive care units, such as ventilators
· Equipment for improving ambient conditions
· Drugs

· Vaccines
· IT applications that may reduce the direct or indirect
consequences of the epidemic
Mobilization of Social Sciences Research on the
Impacts of the COVID-19 Pandemic
In addition to medicinal sciences, TÜBİTAK will launch
a call to reveal the impacts of the COVID-19 pandemic
on socio-economic, social, and industrial developments.
In the scope of social effects, the focus will include
behavioral changes, equality of opportunity, accessibility
of work, education, food supply, communication as well as
psychological and sociological changes. R&D projects will
cover studies that focus on determining the current status
as well as short-, medium-, and long-term projections,
forecasting and analysis studies as well as foresight studies.
These inputs are targeted to be used in creating solutions
to be taken by public institutions, the private sector and
research institutions regarding economic and social
welfare in the future.
Summary of the Science-Based Response to the
COVID-19 Pandemic
The science-based response to the COVID-19 pandemic
that has been implemented by TÜBİTAK involves multiple
fronts. Throughout the process, a key emphasis has been
placed in the realization of the cocreation process that is
supported by evidence-based and qualified knowledge
production as well as qualified human resources. Open
science approaches have been utilized in this process to
support the knowledge base for the cocreation process,
including a new virtual portal, namely the COVID-19
Turkey Web Portal. The web portal has also been effective
in sharing recent scientific developments as well as the
knowledge sources from the virtual conference. TÜBİTAK
is glad to publish a special issue of the Turkish Journal of
Medical Sciences that is dedicated to the sharing of scientific
advances in the special time of a COVID-19 pandemic.
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